Loading...

Home
ETF
PVLA

PVLA

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

PVLA News

Palvella Secures Patent for Skin Disease Treatment

3d agoNewsfilter

Palvella Named Healthcare & Life Sciences Company of the Year at 2026 PACT Awards

May 21 2026Newsfilter

Palvella Releases SELVA and TOIVA Study Data

May 20 2026Newsfilter

Palvella Releases New Data on QTORIN™ Efficacy

May 15 2026Newsfilter

Palvella Therapeutics Successfully Transfers Stock Listing

May 13 2026seekingalpha

Palvella Receives Approval for Nasdaq Global Market Uplisting

May 13 2026Newsfilter

Palvella Therapeutics Q1 2026 Earnings Call Insights

May 08 2026seekingalpha

Palvella Therapeutics Reports Q1 Earnings and Financial Position

May 07 2026seekingalpha

Palvella Initiates Phase 2 Trial for QTORIN Gel in Angiokeratomas

May 04 2026NASDAQ.COM

Palvella Initiates Clinical Trial for Rare Disease Treatment

May 04 2026Newsfilter

Palvella Therapeutics to Report Q1 2026 Financial Results

Apr 30 2026Newsfilter

Palvella Therapeutics Announces Clinical Results Presentation at ISSVA 2026

Apr 20 2026Newsfilter

Palvella Appoints New Board Member to Drive Rare Disease Innovation

Apr 13 2026Newsfilter

Palvella Appoints New Senior Vice President of Sales

Apr 07 2026Newsfilter

Palvella Therapeutics Reports FY Loss and Cash Position

Mar 31 2026seekingalpha

Palvella Plans NDA Submission for QTORIN™ Rapamycin in 2026

Mar 31 2026Newsfilter